COMPANY PROFILE

Shift Bioscience

Explore full profile

Shift Bioscience is unlocking safe rejuvenation with cell simulations

Cambridge, United KingdomFounded 2017Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Shift Bioscience

Shift Bioscience is a biotechnology company that develops drugs to reprogram mitochondrial DNA mutations to address age-related diseases. The company has a cell simulation platform that uses generative AI and a proprietary biological aging clock to predict which gene sets are most likely to be effective in reversing cellular aging. This platform allows them to discover and develop new therapies for a range of age-driven conditions.

Shift Bioscience operates in the biotechnology and longevity market, targeting the significant and growing demand for treatments for age-related diseases. The company's business model is centered around research and development, with the ultimate goal of commercializing its therapies. They have raised $28.6M in funding over 7 rounds from 19 investors, which indicates strong investor confidence in their approach.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Cambridge, United Kingdom
Employees: 24
Open positions: None listed
Dealroom signal: 69.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, BIA Techbio UK, Techbio, Hard Tech, Techbio Drug Discovery, Longevity, Digital Pharma, DT and LS, uk is8 life sciences, science-based
Business model: SaaS
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANT✓Other financing	Apr 2025	$459K	—	UK Research and Innovation	—
SEED✓Equity / VC	Oct 2024	$16M	$64M	Jonathan Milner · F-Prime · Business Growth Fund · Kindred Capital	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Shift Bioscience website traffic

Latest recorded traffic for Shift Bioscience is 2.8K monthly website visits, up 33.3% over the last three months. Shift Bioscience's team declined 4% over the past year.

Latest monthly visits2.8K 3-month web change+33.3% 1-year team growth-4%

Monthly website visitsOct 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
MHMultiomic HealthAI-enabled precision medicine for metabolic syndrome-related conditions	London, United Kingdom	Operational	14	$9.9M	$25M
SYSyntenySynteny’s techbio platform decodes the signal of immune repertoires to power disease discoveries	London, United Kingdom	Operational
CECellVoyantAn AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases	Bristol, United Kingdom	Operational
CACardiaTecApplying artificial intelligence on large-scale human multiomic data to develop the next generation of cardiovascular disease targets	Cambridge, United Kingdom	Operational
RTRelation TherapeuticsUsing machine learning to improve drug discovery	London, United Kingdom	Operational
BABactobioLondon-based biotechnology company using breakthrough technologies in synthetic biology	London, United Kingdom	Operational
MYMytosInfrastructure for fully automated manufacture of any human cell type	London, United Kingdom	Operational
TBT-Cypher Biotcypherbio – Building a pipeline of novel, TCR-based therapeutics.	Oxford, United Kingdom	Operational